Donald R. Dengel, PhD, professor of kinesiology and director of the Laboratory of Integrative Human Physiology (LIHP), is a co-investigator on a grant funded by Ultragenyx Pharmaceutical Inc. 

The 3-year grant titled “Cardiac and Carotid Structure and Function in Patients with Mucopolysaccharidosis Type VII” will examine the longitudinal effects of recombinant human beta-glucuronidase on cardiac and vascular disease in Mucopolysaccharidosis type VII patients.